Actavis Completes Warner Chilcott Acquisition
PR Newswire Association LLC |
In connection with the acquisition,
"The combination of
"Within our
"We are pleased with the performance of this business to date, including a record number of launches and the successful introductions of Minastrin™ 24, Delzicol™ and Doryx® 200 mg. When combined with the global commercial presence of Actavis Pharma and supported by our industry-leading Actavis Global Operations team, we now operate a formidable specialty pharmaceutical company. We have immediately implemented a comprehensive integration process, and will focus our efforts on maximizing our broader portfolio of marketed products, our enhanced research and development capabilities and pipeline and our expanded manufacturing footprint to capture synergies and drive continued growth and value for our shareholders, customers and employees. With the acquisition now closed, we renew our goal of long-term, double-digit organic earnings growth from this newly expanded base."
Financially Compelling Transaction
Additional details on the strengths of the combined companies, including revenue and earnings forecasts and updated synergy targets, will be discussed in more detail during
Review of the Benefits of the Acquisition
The combination represents a significant achievement against
Transforms Actavis Specialty Brands into a Global Competitor
The close of the transaction accelerates Actavis Specialty Brands' evolution into a global competitor and a key growth driver for the new company. The combination provides a 125 percent increase in the number of marketed Specialty Brands products, a 600 percent increase in Specialty Brands pro forma net revenue and more than doubles Women's Health Specialty Brands products with the addition of Actonel®, Lo Loestrin®, Minastrin™ 24, Estrace® and Atelvia® and the recent approval of Lo Minastrin™. It also bolsters Actavis Specialty Brands' Urology business with the addition of the Enablex franchise and establishes a platform for continued expansion into the fast-growing areas of Gastroenterology and Dermatology.
Expands Specialty Brands Industry Leading Pipeline
Actavis Specialty Brands now possess an industry-leading pipeline with more than 25 products in various stages of development, including the combination of strong life cycle management strategies and new exclusive product opportunities for long-term sustainable growth in each therapeutic category. The combination significantly expands
Completes
The dramatically strengthened Actavis Specialty Brands, combined with Actavis Pharma and Actavis Global Operations, forms the foundation of
October 29th Conference Call and Webcast Information
A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00
About
Operating as Actavis Pharma,
For press release and other company information, visit
Statement Required by the Irish Takeover Rules
The directors of
Forward-Looking Statement
Statements contained in this press release that refer to
CONTACTS: Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
David Belian
(862) 261-8141
(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )
SOURCE
Wordcount: | 1958 |
DMV warns customers about scam [Richmond Times-Dispatch, Va.]
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News